Shots:

• Imfinzi has been approved in the EU and the UK for an additional dosing option (1500mg- fd- q4w) in LA- unresectable NSCLC in adults whose tumors express PD-L1 on at least 1% of tumor cells and whose disease has not progressed following platinum-based CRT
• New option extends dosing from 2 to 4wks. thus- reducing medical visits and improving patient convenience. The approval is based on multiple clinical trials that include P-III PACIFIC study in NSCLS patients and P-III CASPIAN study in ES-SCLC patients
• Durvalumab is a human mAb targeting PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80

 ­ Ref: AstraZeneca | Image: Mint